OSE Immunotherapeutics — Lusvertikimab and the future of IBD: KOL insights post-ECCO webinar

In this webinar, OSE Immunotherapeutics joins key opinion leaders Professor Laurent Peyrin-Biroulet, head of the inflammatory bowel disease (IBD) unit at Nancy University Hospital (France); Professor Arnaud Bourreille, gastroenterologist at CHU Nantes (France); and Professor Vipul Jairath, clinical researcher at Schulich School of Medicine & Dentistry (Ontario, Canada), to discuss the evolving treatment landscape in ulcerative colitis and the latest clinical advancements of lusvertikimab (OSE-127). Hosted by healthcare analyst Arron Aatkar from Edison Group, the panel will present key scientific highlights from ECCO 2025, including Phase II CoTikiS trial data, and explore the potential of lusvertikimab in addressing unmet needs in IBD. OSE Immunotherapeutics’ CEO, Nicolas Poirier, also shares insights into the company’s immuno-inflammation pipeline and its broader implications for patient care.

About OSE Immunotherapeutics:

OSE Immunotherapeutics (PAR: OSE) is a leading biotech company committed to pioneering breakthroughs in immuno-oncology and immuno-inflammation. Its lead immuno-inflammation asset is lusvertikimab (formerly OSE-127), an antibody therapy acting as an IL-7R antagonist, which is in clinical development as a potential treatment for ulcerative colitis. It recently completed a Phase II trial (CoTikiS), which met its primary endpoint with statistical significance. OSE’s R&D pipeline is robust and diverse, comprising both proprietary and partnered programmes, ensuring that its progress remains resilient and independent of any singular subsector.